Glenmark Launches Adapalene Gel USP in Pump Packs

Glenmark Therapeutics Inc., USA, has launched Adapalene Gel USP, 0.1% (OTC) in new pump packs. This product is comparable to Differin® Gel, 0.1%. The U.S. OTC Adapalene Gel market achieved approximately $45.8 million in sales for the 52-week period ending September 5, 2026. The new pump packaging aims to enhance consumer convenience and strengthen Glenmark's dermatology portfolio in the U.S. The company is committed to providing high-quality, affordable healthcare solutions.